Potential alternative dosage strategies for patent-protected oral cancer drugs
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.116067 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Austin Wesevich und 2 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology/Oncology, University of Chicago, Chicago, IL, United States. Electronic address: austin.wesevich@uchicagomedicine.org. Hauptthemen laut MEDLINE: Patents as Topic, Antineoplastic Agents, Cost Savings, Drug Costs. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Arnold Ventures LLC, Laura and John Arnold Foundation, National Institutes of Health National Cancer Institute.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Hematology/Oncology, University of Chicago, Chicago, IL, United States. Electronic address: austin.wesevich@uchicagomedicine.org.
- Center for Personalized Therapeutics, University of Chicago, Chicago, IL, United States.
- Section of Hematology/Oncology, University of Chicago, Chicago, IL, United States; Center for Personalized Therapeutics, University of Chicago, Chicago, IL, United States.
Förderung
- Arnold Ventures LLC
- Laura and John Arnold Foundation
- National Institutes of Health National Cancer Institute
Zitieren
APA
Wesevich, A., Schmitt, L. J., & Ratain, M. J. (2025). Potential alternative dosage strategies for patent-protected oral cancer drugs. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.116067
Vancouver
Wesevich A, Schmitt LJ, Ratain MJ. Potential alternative dosage strategies for patent-protected oral cancer drugs. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.116067
BibTeX
@article{Wesevich2025,
author = {Wesevich, Austin and Schmitt, Liam J and Ratain, Mark J},
title = {Potential alternative dosage strategies for patent-protected oral cancer drugs},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.116067}
}
EUVIMED